ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC)

被引：0

作者：

Smith, M. R. ^{[1
]}

Parker, C. C. ^{[2
]}

Saad, F. ^{[3
]}

Miller, K. ^{[4
]}

Tombal, B. ^{[5
]}

Ng, Q. S. ^{[6
]}

Boegemann, M. ^{[7
]}

Matveev, V. ^{[8
]}

Piulats, J. M. ^{[9
]}

Zucca, L. E. ^{[10
]}

Heidenreich, A. ^{[11
]}

Kakehi, Y. ^{[12
]}

Zhang, A. ^{[13
]}

Krissel, H. ^{[14
]}

Shen, J. ^{[15
]}

Wagner, V. ^{[16
]}

Higano, C. ^{[17
,18
]}

机构：

[1] Massachusetts Gen Hosp, Dept Oncol, Boston, MA 02114 USA

[2] Royal Marsden NHS Fdn Trust, Dept Urol, Inst Canc Res, Sutton, Surrey, England

[3] Univ Montreal Hosp Ctr, Dept Urol, Montreal, PQ, Canada

[4] Charite, Dept Med Oncol, Berlin, Germany

[5] Clin Univ St Luc, Dept Urol, Brussels, Belgium

[6] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[7] Univ Munster, Med Ctr, Dept Clin Oncol Urol, Munster, Germany

[8] NN Blokhin Canc Res Ctr, Dept Urol, Moscow, Russia

[9] Catalan Canc Inst, Dept Med Oncol, Barcelona, Spain

[10] Barretos Canc Hosp, Dept Med Oncol, Barretos, Brazil

[11] Univ Hosp Cologne, Dept Urol, Cologne, Germany

[12] Kagawa Univ, Dept Urol, Takamatsu, Kagawa, Japan

[13] Bayer HealthCare Pharmaceut, Oncol, Whippany, NJ USA

[14] Bayer AG, Oncol, Berlin, Germany

[15] Bayer HealthCare Pharmaceut, Clin Stat, Whippany, NJ USA

[16] Bayer Consumer Care AG, Oncol, Basel, Switzerland

[17] Univ Washington, Dept Med Oncol, Seattle, WA 98195 USA

[18] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA30

引用

页数：1

共 50 条

[1] ERA 223: A phase 3 trial of radium-223 dichloride (Ra-223) in combination with abiraterone acetate (abiraterone) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients (pts) with bone predominant metastatic castration-resistant prostate cancer (mCRPC).
Smith, Matthew Raymond
Parker, Chris
Tombal, Bertrand F.
Miller, Kurt
Saad, Fred
Fang, Fang
Zhang, Amily
Kornacker, Martin
Higano, Celestia S.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[2] Era 223-A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapynaive patients with bone-predominant metastatic Castration Resistant Prostate Cancer (Crpc)
Bracarda, S.
Procopio, G.
Parker, C.
Tombal, B.
Miller, K.
Saad, F.
Fang, F.
Zhang, A.
Kornacker, M.
Higano, C.
Smith, M. R.
ANNALS OF ONCOLOGY, 2015, 26 : 57 - 57
[3] ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-na ve patients with bone-predominant metastatic castration-resistant prostate cancer.
Smith, Matthew R.
Parker, Chris C.
Tombal, Bertrand F.
Miller, Kurt
Saad, Fred
Shen, Junwu
Zhang, Amily
Kornacker, Martin
Higano, Celestia S.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[4] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Petrylak, D. P.
Vaishampayan, U. N.
Patel, K. R.
Higano, C. S.
Albany, C.
Dawson, N. A.
Mehlhaff, B. A.
Quinn, D. I.
Nordquist, L. T.
Wagner, V. J.
Shen, J.
Trandafir, L.
Sartor, O.
ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
[5] Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety.
Emamekhoo, Hamid
Chowdry, Rajasree Pia
Elson, Paul
Ledet, Elisa M.
Martin, Allison
Cotogno, Patrick
Beach, Jennifer
Steinberger, Allie E.
Allman, Kimberly D.
Stolten, Michael
Garcia, Jorge A.
Sartor, Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
[6] Radium-223 Is the Preferred Therapy in Bone-Predominant Symptomatic Metastatic Castration-Resistant Prostate Cancer
Dreicer, Robert
Li, Jing
Andrew, J.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 293 - +
[7] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Palmedo, H.
Ahmadzadehfar, H.
Eschmann, S.
Selkinski, I.
Straube, F.
Niesen, A.
Schoenberger, J.
Barsegian, V.
Liepe, K.
Mottaghy, F. M.
Guan, R.
Pinkert, J.
Buetikofer, S.
Herrmann, K.
ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
[8] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Morris, Michael J.
De Wit, Ronald
Vogelzang, Nicholas J.
Tagawa, Scott T.
Higano, Celestia S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Morris, Michael J.
De Wit, Ronald
Vogelzang, Nicholas J.
Tagawa, Scott T.
Higano, Celestia S.
Hamberg, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Palmedo, H.
Eschmann, S.
Werner, A.
Selinski, I.
Moellers, M-O.
Kalinovsky, J.
Benson, A.
Poeppel, T.
ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336

← 1 2 3 4 5 →